The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Renal denervation for treatment of hypertension – will 2017 be the year of enlightenment?
EuroIntervention 2017;12:e2163-e2165 published online e-edition April 2017. DOI: 10.4244/EIJV12I18A355
Felix Mahfoud1,2*, MD; Elazer R. Edelman2,3, MD, PhD
1. Klinik für Innere Medizin III, Saarland University Hospital, Homburg/Saar, Germany; 2. Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA; 3. Cardiovascular Division, Brigham and Women’s Hospital, H
Hypertension is accompanied by significant adverse cardiovascular outcomes, and intensive blood pressure lowering (<120 mmHg) in patients at risk improves outcomes1. However, although numerous highly effective pharmacological therapies are available to lower blood pressure, control rates remain unacceptably low. A substantial number of patients with hypertension are reluctant or incapable of adhering to lifestyle modification and/or poly pharmacotherapy regimens, especially as the former has a time-delimited impact on blood pressure and the latter requires a lifetime of adherence, which is challenging at best. Non-pharmacological control of blood pressure is appealing, and several interventional approaches have been developed and ...